T-Cell Non-Hodgkin Lymphoma CRISPR Cell Models for Drug Discovery

According to the World Health Organization (WHO) GLOBOCAN 2020, non-Hodgkin lymphoma (NHL) accounts for approximately 544,000 new cases and 260,000 deaths annually worldwide. T-cell non-Hodgkin lymphoma (T-NHL) represents about 10-15% of all NHL cases, with an incidence of roughly 2-3 per 100,000 person-years. The National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) program reports a 5-year relative survival rate of approximately 60% for all T-NHL subtypes, though this varies significantly by subtype: for anaplastic large cell lymphoma (ALCL), 5-year survival is around 70-80%, while for peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), it is only 30-40%. Key risk factors include Epstein-Barr virus (EBV) infection, human T-cell leukemia virus type 1 (HTLV-1), and inherited immunodeficiencies. The aggressive nature and poor prognosis of many T-NHL subtypes underscore the urgent need for improved therapeutic strategies and preclinical models.

T-NHL is an ideal disease for mechanistic studies due to its well-defined subtypes, each with distinct genetic and molecular profiles. Public datasets from The Cancer Genome Atlas (TCGA) and the Catalogue of Somatic Mutations in Cancer (COSMIC) provide extensive genomic data, including mutations in NOTCH1, TP53, and JAK/STAT pathway genes. Open questions include the role of tumor microenvironment interactions, mechanisms of chemoresistance, and identification of novel therapeutic targets. Gene-edited cell models, such as CRISPR knockouts and isogenic lines, are essential tools for dissecting these pathways and validating targets in a controlled genetic background.

The pathogenesis of T-NHL involves several key pathways:

1. NOTCH1 Signaling:

• • Activating mutations in NOTCH1 (e.g., in T-cell acute lymphoblastic leukemia/lymphoma, T-ALL) lead to constitutive activation of the NOTCH1 receptor.
• • This promotes cell proliferation and survival through downstream targets such as MYC and HES1.

2. JAK/STAT Pathway:

• • Mutations in JAK1, JAK3, or STAT3/STAT5B are common in T-NHL, particularly in PTCL and ALCL.
• • Constitutive activation of JAK/STAT signaling drives uncontrolled cell growth and immune evasion.

3. PI3K/AKT/mTOR Pathway:

• • Loss of PTEN or activating mutations in PI3KCA lead to hyperactivation of the PI3K/AKT/mTOR axis.
• • This pathway supports cell survival, metabolism, and resistance to apoptosis.

4. TP53 Tumor Suppressor:

• • Inactivating mutations or deletions in TP53 are frequent in aggressive T-NHL subtypes.
• • Loss of p53 function impairs DNA damage response and apoptosis, contributing to genomic instability.

Data derived from TCGA and COSMIC databases.

Key deregulated networks in T-NHL include:

• • NOTCH1-MYC Axis:
• • NOTCH1 directly upregulates MYC, driving cell cycle progression.
• • MYC also feeds back to enhance NOTCH1 expression.
• • JAK/STAT-Immune Evasion:
• • Constitutive STAT3/5 activation upregulates PD-L1 expression, enabling immune escape.
• • STAT3 also promotes expression of anti-apoptotic proteins like BCL2.
• • PI3K/AKT/mTOR:
• • AKT phosphorylates and inactivates pro-apoptotic factors (BAD, FOXO).
• • mTORC1 activation increases protein synthesis and cell growth.
• • TP53-DNA Damage Response:
• • Loss of p53 leads to failure in cell cycle arrest and apoptosis after DNA damage.
• • This contributes to chemoresistance and accumulation of secondary mutations.

Organoid models derived from patient tumors offer advantages such as preservation of the tumor microenvironment and clonal heterogeneity. They are increasingly used for drug sensitivity testing and studying cell-cell interactions.

Common animal models for T-NHL include:

• • Patient-Derived Xenografts (PDX):
• • Engraftment of human T-NHL cells into immunodeficient mice (e.g., NSG).
• • Retains patient-specific genetic and phenotypic features.
• • Used for preclinical drug testing and biomarker studies.
• • Genetically Engineered Mouse Models (GEMM):
• • Conditional knockout of PTEN or TP53 in T-cell lineage.
• • Transgenic expression of NOTCH1 intracellular domain (NICD) in T-cells.
• • Models recapitulate human T-ALL/lymphoma with high fidelity.
• • Induced Models:
• • Injection of T-NHL cell lines (e.g., Jurkat) into mice to form subcutaneous or disseminated tumors.
• • Useful for rapid in vivo screening of drug efficacy.

CRISPR/Cas9 technology enables the generation of isogenic cell lines with precise genetic modifications, providing powerful tools for functional studies. For example:

• • TP53 knockout in Jurkat cells: Models loss of p53 function, allowing investigation of chemoresistance mechanisms.
• • NOTCH1 knock-in (activating mutation) in T-cell lines: Recapitulates constitutive NOTCH1 signaling for drug target validation.
• • JAK3 A572V knock-in: Enables study of JAK/STAT pathway activation and screening of JAK inhibitors.

Commercially available, sequence-verified gene-edited cell models accelerate research by eliminating the need for in-house editing and validation. These models are produced using ribonucleoprotein (RNP) complexes or plasmid-based CRISPR systems, with clonal selection and Sanger sequencing confirmation. They are widely used in drug discovery, target validation, and functional genomics studies.

Gene-edited cell lines are essential for validating the role of specific genes in T-NHL pathogenesis. For example:

• • Knockout of NOTCH1 in Jurkat cells reduces proliferation and induces apoptosis, confirming its oncogenic role.
• • Knock-in of STAT5B N642H in normal T-cells leads to increased STAT5 phosphorylation and cytokine-independent growth, demonstrating its transforming potential.
• • TP53 knockout in T-NHL cell lines sensitizes cells to DNA-damaging agents, highlighting p53-dependent drug responses.

Isogenic cell line pairs (e.g., wild-type vs. TP53 knockout) are used in high-throughput drug screens to identify compounds that selectively target mutant cells. For example:

• • Screens with TP53-null T-NHL cells have identified synthetic lethal partners such as WEE1 inhibitors.
• • Resistance modeling: Chronic exposure of isogenic lines to targeted therapies (e.g., JAK inhibitors) can reveal acquired resistance mutations, such as secondary JAK3 mutations.
• • Combination screening: Gene-edited models help identify synergistic drug combinations that overcome resistance.

CRISPR-based synthetic lethality screens in T-NHL cell lines can identify novel biomarkers and therapeutic targets. For example:

• • A genome-wide CRISPR screen in PTEN-null T-NHL cells identified mTORC1 components as essential for survival, suggesting mTOR inhibitors as a targeted therapy.
• • Screens in NOTCH1-mutant cells revealed dependency on the gamma-secretase complex, validating gamma-secretase inhibitors as a therapeutic strategy.
• • Loss-of-function screens can identify genes whose knockout sensitizes T-NHL cells to chemotherapy, providing candidate biomarkers for patient stratification.